A Medical Device Daily

The Johns Hopkins University Applied Physics Laboratory (APL; Laurel, Maryland) has signed an agreement with Hologic (Bedford, Massachusetts), granting it exclusive, worldwide rights to the lab's bone health analysis technology.

Hologic is a provider of diagnostic imaging and digital imaging systems directed towards women's health, including bone densitometry equipment.

"This is a great example of the types of collaborations that are needed to move government-funded technologies into the public sector," said Heather Curran, marketing and technology manager in the APL Office of Technology Transfer. "This work was originally funded, in part, to help astronauts. This agreement ensures that many more people will benefit from this technology."

The Hip Structure Analysis (HSA) technology was developed through the collaborative efforts of Drs. Thomas Beck and Harry Charles, along with Howard Feldmesser and Thomas Magee.

Beck, an associate professor of radiology in the Johns Hopkins University School of Medicine (Baltimore), is a "world leader" in the development of biomechanical parameters of hip structure derived from densitometric information, according to Johns Hopkins. His HSA method and its prediction of bone strength has been the subject of more than 30 peer-reviewed publications.

Ceragenix Pharmaceuticals (Denver), a development-stage biopharmaceutical company, said it has entered into a Cooperative Research and Development Agreement (CRADA) with the Centers for Disease Control and Prevention (CDC; Atlanta) to evaluate the efficacy of Ceragenix's Ceracide antimicrobial coating for the prevention of bacterial biofilm growth on medical devices.

The company had previously announced entering into a letter of intent with the CDC on this project.

"This collaboration with the CDC illustrates the progress we continue to make with our infectious disease program," said Steven Porter, chairman and CEO of Cera-genix.

The CRADA's research plan will evaluate Ceragenix's Ceracide antimicrobial coating using the CDC's Biofilm Reactor, a device that is able to reproducibly grow biofilms in an environment mimicking the body conditions under which bacteria form such films, including fluid turbulence.

Devon Medical Supplies (King of Prussia, Pennsylvania) has partnered with Safe Medical Solutions to launch a nationwide co-marketing effort of cost-effective safety medical products.

The companies will market the new NeedleZap, a portable needle-destruction device distributed by Safe Medical Solutions, in conjunction with Devon Medical's line of hypodermic and insulin syringes.

The NeedleZap is designed to reduce the chances of needlestick injuries and is compliant with Occupational Health and Safety Administration requirements concerning blood-borne pathogens, the company said. The companies also plan to offer Devon Medical's SafeTip syringe technology, which is under development and expected to undergo FDA review in 2Q06.

No Comments